New Clinical Study Proves Skinvisible's DermSafe Kills the H1N1 Swine Flu Virus

November 12, 2009

More Positive Results for Unique Hand Sanitizer

Las Vegas, Nevada - November 12, 2009 - Skinvisible, Inc. (SKVI:OTCBB), a pharmaceutical research and development company announced today that it has successfully completed a new clinical study proving that its hand sanitizer lotion DermSafe® kills/inactivates the H1N1 virus on humans. This in-vivo study proves that DermSafe meets the criteria set-out by internationally accepted study guidelines to show efficacy against the H1N1 "swine flu" virus.

The study, performed at the independent testing laboratory Bioscience Laboratories, Inc., required that the subjects' finger pads be contaminated with the H1N1 virus and then examined according to the American Society for Testing and Materials (ASTM) Standards. The results of the study proved that DermSafe killed the virus to the same detection level as 70% alcohol. In some countries, this study allows Skinvisible to submit data for approval to include "Kills H1N1" on the product label. This further confirms the efficacy of DermSafe as previously announced in an in-vitro study conducted at Retroscreen Virology, where DermSafe also achieved a 99.99% kill / inactivation of the H1N1 virus.

Furthermore, DermSafe was also successfully tested in an in-vivo bacterial hand disinfection study using the European Standard Method. This study method is used in a number of countries in Europe and also in Canada for approval in the healthcare and food services industries. The results proved the efficacy of DermSafe against bacteria on artificially contaminated hands as compared to the reference product of 60% isopropanol, a typical alcohol used in hand sanitizers.

"We are very pleased with the clinical results DermSafe achieved in these two studies," said Mr. Terry Howlett, President and CEO of Skinvisible. "This proves that DermSafe is an effective alternative to alcohol, without the drying and safety issues. It also represents an important milestone to accelerate our license negotiations in various countries as these studies are required for regulatory approval in some jurisdictions. We also expect these additional studies will solidify and expedite further approvals globally."

DermSafe is formulated with Skinvisible's patented technology Invisicare®, a polymer delivery system that is proven to bind to skin and resist wash-off for up to four hours, thereby providing continuous antimicrobial protection. The active ingredient in DermSafe is chlorhexidine gluconate 4%, which has been safely used in hospital surgery rooms worldwide for over fifty years as a pre-surgical hand scrub.

About Invisicare®

Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives and reduce irritation. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. www.skinvisible.com

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending June 30, 2009).

Press Release Index

Click here to join our mailing list.